OBJECTIVE: Cancer-related anaemia is associated with fatigue that adversely affects patients' everyday functioning and wellbeing. We explore the impact of fatigue on patient productivity and caregiver burden. METHODS: The analyses are based on data from a randomised, open-label, active-controlled, dose-finding trial of darbepoetin alfa among solid-tumour cancer patients with anaemia, who are receiving chemotherapy. Fatigue is assessed with the Functional Assessment of Cancer Therapy (FACT)-Fatigue subscale score. Productivity and caregiver outcomes include time (hours) missed from usual activities, amount of assistance (hours) needed from others, overall ability to perform desired activities and ability to perform family responsibilities. These outcomes are assessed at baseline and the end of the 12-week treatment period. ANOVA and linear regression models are used to evaluate associations. RESULTS:Patients (n=300) were aged 61 years on average, with a mean (SD) baseline haemoglobin of 9.9 (0.9) g/dL. FACT-Fatigue subscale score improvements were significantly (p=0.003) associated with haemoglobin improvements. Over a 2-week period, after controlling for age, sex and disease progression, one-point improvements in FACT-Fatigue subscale scores corresponded to a 1-hour (95% CI 0.5, 1.5) gain in productive time, 0.7-hour (95% CI 0.4, 1.0) reduction in caregiver time and 1.6% (95% CI 1.4, 1.7) improvement in overall activity. CONCLUSIONS: Reducing fatigue is associated with gains in productive time, reductions in caregiver burden and enhanced ability to perform activities. These outcomes may have broader implications for patients' wellbeing and for the societal impact of cancer-related fatigue and anaemia.
RCT Entities:
OBJECTIVE:Cancer-related anaemia is associated with fatigue that adversely affects patients' everyday functioning and wellbeing. We explore the impact of fatigue on patient productivity and caregiver burden. METHODS: The analyses are based on data from a randomised, open-label, active-controlled, dose-finding trial of darbepoetin alfa among solid-tumour cancerpatients with anaemia, who are receiving chemotherapy. Fatigue is assessed with the Functional Assessment of Cancer Therapy (FACT)-Fatigue subscale score. Productivity and caregiver outcomes include time (hours) missed from usual activities, amount of assistance (hours) needed from others, overall ability to perform desired activities and ability to perform family responsibilities. These outcomes are assessed at baseline and the end of the 12-week treatment period. ANOVA and linear regression models are used to evaluate associations. RESULTS:Patients (n=300) were aged 61 years on average, with a mean (SD) baseline haemoglobin of 9.9 (0.9) g/dL. FACT-Fatigue subscale score improvements were significantly (p=0.003) associated with haemoglobin improvements. Over a 2-week period, after controlling for age, sex and disease progression, one-point improvements in FACT-Fatigue subscale scores corresponded to a 1-hour (95% CI 0.5, 1.5) gain in productive time, 0.7-hour (95% CI 0.4, 1.0) reduction in caregiver time and 1.6% (95% CI 1.4, 1.7) improvement in overall activity. CONCLUSIONS: Reducing fatigue is associated with gains in productive time, reductions in caregiver burden and enhanced ability to perform activities. These outcomes may have broader implications for patients' wellbeing and for the societal impact of cancer-related fatigue and anaemia.
Authors: Joel D Kallich; N Simon Tchekmedyian; Anne M Damiano; Jinhai Shi; Jeanne T Black; M Haim Erder Journal: Oncology (Williston Park) Date: 2002-09 Impact factor: 2.990
Authors: G A Curt; W Breitbart; D Cella; J E Groopman; S J Horning; L M Itri; D H Johnson; C Miaskowski; S L Scherr; R K Portenoy; N J Vogelzang Journal: Oncologist Date: 2000
Authors: Anders Osterborg; Y Brandberg; V Molostova; G Iosava; K Abdulkadyrov; M Hedenus; D Messinger Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: Michael Hedenus; Magnus Adriansson; Jesus San Miguel; Mark H H Kramer; Martin R Schipperus; Eeva Juvonen; Kerry Taylor; Andrew Belch; Albert Altés; Giovanni Martinelli; David Watson; James Matcham; Gregory Rossi; Timothy J Littlewood Journal: Br J Haematol Date: 2003-08 Impact factor: 6.998
Authors: Johan Vansteenkiste; Robert Pirker; Bartomeu Massuti; Fernando Barata; Albert Font; Michael Fiegl; Salvatore Siena; Jenni Gateley; Dianne Tomita; Alan B Colowick; Jaromir Musil Journal: J Natl Cancer Inst Date: 2002-08-21 Impact factor: 13.506
Authors: J A Glaspy; J S Jadeja; G Justice; J Kessler; D Richards; L Schwartzberg; N S Tchekmedyian; S Armstrong; J O'Byrne; G Rossi; A B Colowick Journal: Br J Cancer Date: 2002-07-29 Impact factor: 7.640
Authors: B O'Connor; M Markicevic; L Newman; R K Poduval; E Tiernan; E Hanrahan; S Cuffe; R B Reilly; D Walsh Journal: Support Care Cancer Date: 2018-11-22 Impact factor: 3.603
Authors: Leah Kleinman; Katy Benjamin; Hema Viswanathan; Maria Stoeckl Mattera; Linda Bosserman; Douglas W Blayney; Dennis A Revicki Journal: Qual Life Res Date: 2011-10-11 Impact factor: 4.147
Authors: Lanfang Xu; Hairong Xu; Kimberly Cannavale; Olivia Sattayapiwat; Roberto Rodriguez; John H Page; Chun Chao Journal: Support Care Cancer Date: 2016-02-12 Impact factor: 3.603
Authors: David H Henry; Hema N Viswanathan; Eric P Elkin; Shana Traina; Shawn Wade; David Cella Journal: Support Care Cancer Date: 2008-01-17 Impact factor: 3.603